212 related articles for article (PubMed ID: 16547349)
1. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects.
Raduner S; Majewska A; Chen JZ; Xie XQ; Hamon J; Faller B; Altmann KH; Gertsch J
J Biol Chem; 2006 May; 281(20):14192-206. PubMed ID: 16547349
[TBL] [Abstract][Full Text] [Related]
2. Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides.
Raduner S; Bisson W; Abagyan R; Altmann KH; Gertsch J
J Nat Prod; 2007 Jun; 70(6):1010-5. PubMed ID: 17497806
[TBL] [Abstract][Full Text] [Related]
3. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways.
Gertsch J; Schoop R; Kuenzle U; Suter A
FEBS Lett; 2004 Nov; 577(3):563-9. PubMed ID: 15556647
[TBL] [Abstract][Full Text] [Related]
4. Echinacea and its alkylamides: effects on the influenza A-induced secretion of cytokines, chemokines, and PGE₂ from RAW 264.7 macrophage-like cells.
Cech NB; Kandhi V; Davis JM; Hamilton A; Eads D; Laster SM
Int Immunopharmacol; 2010 Oct; 10(10):1268-78. PubMed ID: 20674883
[TBL] [Abstract][Full Text] [Related]
5. Role for PPARgamma in IL-2 inhibition in T cells by Echinacea-derived undeca-2E-ene-8,10-diynoic acid isobutylamide.
Spelman K; Iiams-Hauser K; Cech NB; Taylor EW; Smirnoff N; Wenner CA
Int Immunopharmacol; 2009 Oct; 9(11):1260-4. PubMed ID: 19712756
[TBL] [Abstract][Full Text] [Related]
6. Purification of alkylamides from Echinacea angustifolia (DC.) Hell. Roots by high-speed countercurrent chromatography.
Lopes-Lutz D; Mudge E; Ippolito R; Brown P; Schieber A
J Agric Food Chem; 2011 Jan; 59(2):491-4. PubMed ID: 21190380
[TBL] [Abstract][Full Text] [Related]
7. Mast cell degranulation and calcium influx are inhibited by an Echinacea purpurea extract and the alkylamide dodeca-2E,4E-dienoic acid isobutylamide.
Gulledge TV; Collette NM; Mackey E; Johnstone SE; Moazami Y; Todd DA; Moeser AJ; Pierce JG; Cech NB; Laster SM
J Ethnopharmacol; 2018 Feb; 212():166-174. PubMed ID: 29042288
[TBL] [Abstract][Full Text] [Related]
8. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts.
Chicca A; Raduner S; Pellati F; Strompen T; Altmann KH; Schoop R; Gertsch J
Int Immunopharmacol; 2009 Jul; 9(7-8):850-8. PubMed ID: 19303464
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
10. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
11. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective synthesis, natural occurrence and CB(2) receptor binding affinities of alkylamides from herbal medicines such as Echinacea sp.
Matovic N; Matthias A; Gertsch J; Raduner S; Bone KM; Lehmann RP; Devoss JJ
Org Biomol Chem; 2007 Jan; 5(1):169-74. PubMed ID: 17164922
[TBL] [Abstract][Full Text] [Related]
13. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
14. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
16. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
17. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.
Woelkart K; Xu W; Pei Y; Makriyannis A; Picone RP; Bauer R
Planta Med; 2005 Aug; 71(8):701-5. PubMed ID: 16142631
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content.
Modarai M; Gertsch J; Suter A; Heinrich M; Kortenkamp A
J Pharm Pharmacol; 2007 Apr; 59(4):567-73. PubMed ID: 17430641
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4).
Modarai M; Yang M; Suter A; Kortenkamp A; Heinrich M
Planta Med; 2010 Mar; 76(4):378-85. PubMed ID: 19790031
[TBL] [Abstract][Full Text] [Related]
20. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors.
Gertsch J; Raduner S; Altmann KH
J Recept Signal Transduct Res; 2006; 26(5-6):709-30. PubMed ID: 17118807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
